Enrollment Milestone for SLS009: Phase 2 AML Trial Targets Patients Least Likely to Respond to Standard Therapy

First Patient Enrolled in High-Need AML Subgroups—Precision Medicine and AI at the Forefront

SELLAS Life Sciences (NASDAQ: SLS) has announced the enrollment of the first patient in its randomized Phase 2 clinical trial evaluating SLS009 (tambiciclib), a highly selective CDK9 inhibitor, for newly diagnosed, first-line acute myeloid leukemia (AML) patients. The study aims to enroll about 80 patients in the US and Europe—specifically those who are unlikely to benefit from conventional Venetoclax/Azacitidine (Aza/Ven) therapy.

Patient Cohorts Chosen for Unmet Needs—A Strategic Leap

Unlike broad AML studies, this trial is deliberately designed around subgroups where standard therapy falls short. By focusing on molecularly-defined populations and those at risk for early non-response, SELLAS leverages both predictive biomarkers and AI-assisted precision medicine models—essential tools as oncology increasingly moves toward highly tailored treatment plans.

Topline results are expected in Q4 2026, with the trial drawing on FDA guidance and robust prior Phase 2 data that already showed high efficacy for SLS009 in patients with poor-prognosis AML subtypes.

Previous Phase 2 Results Highlight Subgroup Response—Data Table Illustrates Key Outcomes

The most compelling evidence for SLS009’s promise comes from SELLAS’ earlier Phase 2 study in relapsed/refractory (r/r) AML, which exceeded primary benchmarks for both safety and efficacy, particularly in tough-to-treat molecular profiles. Here’s a breakdown of the outcomes:

In the highest risk groups, SLS009 almost doubled the median overall survival compared to best available therapies, with notable improvements in genetically defined subtypes (such as ASXL1 mutations), which are typically associated with poor prognosis.

AI-Assisted Precision Medicine: SELLAS Leverages Next-Gen Models

SELLAS is applying AI-driven biomarker models to guide patient selection and optimize therapy outcomes. This approach not only supports clinical trial success but also potentially accelerates real-world market adoption if phase results hold up in the larger population.

Key Takeaway: SLS009 Study Could Redefine Frontline AML Treatment—Early Results Are Promising

The new Phase 2 trial isn’t just business as usual—its strategy to enroll the patients least likely to succeed on standard Aza/Ven therapy puts the SLS009 program at the center of precision oncology. If the topline data, expected in late 2026, mimics or improves upon the strong response rates of previous studies, SLS009 could become a targeted lifeline for patients facing the toughest odds with frontline AML.

Investors and clinicians alike should pay close attention to SELLAS’ ongoing updates, as this targeted, data-driven approach could represent a broader trend toward more selective and effective cancer treatments across the biopharma industry.

Contact Information:

If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.

About the Publisher - Marketchameleon.com:

Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.

NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.

The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.

Disclosure: This article was generated with the assistance of AI